FAKTOR-OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Real-time Bid/Ask 09:22:10 24/05/2024 pm IST | ||
| 7.2 EUR / 7.3 EUR | +0.69% |
|
| Current month | -28.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 7.1 | -1.39% |
| 23/24/23 | 7.2 | +1.41% |
| 22/24/22 | 7.1 | +4.26% |
| 21/24/21 | 6.81 | -5.29% |
| 20/24/20 | 7.19 | -10.35% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 09:19 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG35FA |
| ISIN | DE000MG35FA2 |
| Date issued | 26/04/2024 |
| Strike | 352.3 $ |
| Maturity | Unlimited |
| Parity | 15.53 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.46 € |
|---|---|
| Lowest since issue | 6.52 € |
| Spread | 0.1 € |
| Spread % | 1.41% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
234.8
USD
Average target price
363.9
USD
Spread / Average Target
+54.93%
- Stock Market
- Certificates
- Certificat
